Anticancer composition, especially for treating melanoma, containing peptide with L-m-sarcolysine residue(s) as active agent and cyclodextrin sulfoalkyl ether as carrier providing high bioavailability

摘要

In a pharmaceutical composition (A) for treating cancer diseases, containing a peptide compound (I) in delayed release form as active agent, (a) (I) is selected from six specific tri-, tetra- or pentapeptides containing at least one L-m-sarcolysine residue and (b) (A) additionally contains a cyclodextrin (II), containing at least one sulfoalkyl ether salt substituent, as auxiliary or carrier. In a pharmaceutical composition (A) for treating cancer diseases, containing at least one peptide compound (I) in delayed release form as active agent, (a) (I) is selected from L-seryl-L-p-fluorophenylalanyl-L-m-sarcolysine, L-prolyl-L-m-sarcolysyl-L-p-fluorophenylalanine (Ia), L-m-sarcolysyl-N-nitro-L-arginyl-L-norvaline, L-p-fluorophenylalanyl-L-m-sarcolysyl-L-asparagine, L-p-fluorophenylalanyl-glycyl-L-m-sarcolysyl-L-norvaline and L-m-sarcolysyl-L-arginyl-L-lysyl-L-m-sarcolysyl-L-histidine (or their lower alkyl esters and/or acid addition salts) and (b) (A) additionally contains at least one substituted cyclodextrin (II), containing at least one substituent of formula -O-R-SO3-.M+, as auxiliary or carrier. R = 2-6C alkylene; M+ = counter-ion.